EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Designing novel bisquinoline antimalarials from historical 4-aminoquinolines to combat drug-resistant malaria

Mason J Handford iD, Yuexin Li, Terry Riscoe, Xiaowei Zhang, Jane X Kelly, Michael K Riscoe iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01300-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Mason J Handford und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Physiology and Biochemistry Department, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Antimalarials, Aminoquinolines, Plasmodium falciparum, Malaria, Falciparum. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, U.S. Department of Defense, U.S. Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasmodium falciparum, the deadliest causative agent of malaria, continues to evade eradication efforts through widespread drug resistance. The recent development of ADC-028 , a 4-aminoquinoline antimalarial with excellent activity and pharmacokinetic properties, prompted the investigation of bisquinoline analogs featuring similar structural motifs. Here, we describe a structure-activity relationship study that guided the optimization of compounds with key features, including the 4-anilinoquinoline core and diverse bridging linkers. Several analogs exhibited potent in vitro activity (IC 50 < 20 nM) against both drug-sensitive and multidrug-resistant P. falciparum strains, while maintaining favorable cytotoxicity profiles. Among them, 25 demonstrated improved intrinsic metabolic stability (t 1/2 = 121 min) and potent in vivo efficacy (ED 50 = 0.32 mg/kg/day), achieving complete curative protection at a reduced dose compared to ADC-028. While 25 showed moderately reduced oral bioavailability (F = 43%) and a shorter half-life (T 1/2 = 27.2 h) relative to ADC-028, its enhanced in vivo efficacy underscores its therapeutic potential. This work highlights a promising path forward in developing antimalarials that retain the efficacy of legacy compounds while overcoming modern resistance mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsAminoquinolinesPlasmodium falciparumMalaria, FalciparumQuinolinesAnimalsStructure-Activity RelationshipHumansMiceDrug Resistance

Stichwörter der Autor:innen

4-aminoquinolinePlasmodium falciparumantimalarial agentsmalariamultidrug-resistant malaria

Substanzen

AntimalarialsAminoquinolines4-aminoquinolineQuinolines

Autor:innen und Institutionen

  • Chemical Physiology and Biochemistry Department, Oregon Health & Science University, Portland, Oregon, USA.
  • Experimental Chemotherapy Lab, Portland VA Research Foundation, Portland, Oregon, USA.
  • Department of Chemistry, Portland State University, Portland, Oregon, USA.
  • Molecular Microbiology and Immunology Department, Oregon Health & Science University, Portland, Oregon, USA.

ORCID-Profile: Mason J Handford, Michael K Riscoe

Förderung

  • NIH HHS
  • U.S. Department of Defense
  • U.S. Department of Veterans Affairs
  • National Institutes of Health

Zitieren

APA

Handford, M. J., Li, Y., Riscoe, T., Zhang, X., Kelly, J. X., & Riscoe, M. K. (2026). Designing novel bisquinoline antimalarials from historical 4-aminoquinolines to combat drug-resistant malaria. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01300-25

Vancouver

Handford MJ, Li Y, Riscoe T, Zhang X, Kelly JX, Riscoe MK. Designing novel bisquinoline antimalarials from historical 4-aminoquinolines to combat drug-resistant malaria. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01300-25

BibTeX
@article{Handford2026,
  author = {Handford, Mason J and Li, Yuexin and Riscoe, Terry and Zhang, Xiaowei and Kelly, Jane X and Riscoe, Michael K},
  title = {Designing novel bisquinoline antimalarials from historical 4-aminoquinolines to combat drug-resistant malaria},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01300-25}
}
Kostenlos starten →